Liu Tingting, Chen Yanjun, Hou Lianjie, Yu Yulu, Ma Dan, Jiang Ting, Zhao Guojun
Affiliated Qingyuan Hospital, Guangzhou Medical University, Qingyuan People's Hospital, Qingyuan, Guangdong, China.
Department of Pathology, Southwest Hospital, Third Military Medical University, Chongqing, China.
Front Cardiovasc Med. 2024 Aug 21;11:1450737. doi: 10.3389/fcvm.2024.1450737. eCollection 2024.
Atherosclerosis is a chronic inflammatory disease characterized by innate and adaptive immune responses, which seriously threatens human life and health. It is a primary cause of coronary heart disease, myocardial infarction, and peripheral vascular disease. Research has demonstrated that immune cells are fundamental to the development of atherosclerosis and chronic inflammation. Therefore, it is anticipated that immunotherapy targeting immune cells will be a novel technique in the management of atherosclerosis. This article reviews the growth of research on the regulatory role of immune cells in atherosclerosis and targeted therapy approaches. The purpose is to offer new therapeutic approaches for the control and treatment of cardiovascular illnesses caused by atherosclerosis.
动脉粥样硬化是一种以先天性和适应性免疫反应为特征的慢性炎症性疾病,严重威胁人类生命健康。它是冠心病、心肌梗死和外周血管疾病的主要病因。研究表明,免疫细胞是动脉粥样硬化和慢性炎症发展的基础。因此,预计针对免疫细胞的免疫疗法将成为治疗动脉粥样硬化的一项新技术。本文综述了免疫细胞在动脉粥样硬化中的调节作用及靶向治疗方法的研究进展。目的是为控制和治疗由动脉粥样硬化引起的心血管疾病提供新的治疗方法。